Phase 2 N=216 Polypill For Prevention of Cardiovascular Disease
Cardiovascular Disease
Primary: Reduction of the Estimated 10-year Total Cardiovascular Risk Score — 11.5; 11.1 percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Phase 2 N=27 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Anaplastic Astrocytoma
Primary: Number of Participants With Objective Response — 2; 3; 6; 10 Participants
Phase 2 N=35 Breast Cancer Risk Biomarkers in Postmenopausal Women
Breast Cancer
Primary: The Proportion of Subjects That Complete Intervention of Lovaza™ 4 Grams Per Day — 0.97 proportion of enrolled participants
Phase 2 N=13 Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05
Phase 2 N=126 Post-Myocardial Infarction Remodeling Prevention Therapy
Acute Myocardial Infarction · Pacing Therapy · Cardiac Remodeling
Primary: Change in Left Ventricular End Diastolic Volume (LVEDV) — 16.4; 15.8 mL
Phase 2 N=13 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Thyroid Neoplasm
Primary: RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment — 6; 1; 1; 0 Participants
Phase 2 N=21 Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Number of Participants With Partial and Complete Response. — 1 participant
Phase 2 N=10 Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Sialorrhea
Primary: Objectively Measured Salivary Weight — -0.07; -0.68 gm
Phase 2 N=32 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma · Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor
Primary: Efficacy of Belinostat in Terms of Complete or Partial Response; Disappearance of All Target Lesions or at Least a 30% Decrease in the Sum of the Longest Diameter of…
Phase 2 N=105 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
Pulmonary Tuberculosis
Primary: Early Bactericidal Activity (EBA) Measured as the Daily Rate of Change in log10 CFUs (Colony Forming Units) of M. Tuberculosis in Sputum on Solid Media (Days 0-14)…
Phase 2 N=19 Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma
Lipoma
Primary: Percent Change From Baseline in Surface Area of the Lipoma at Six Months — -81.277; 2.053 percentage change from baseline — p=<0.0001
Phase 2 N=18 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Phase 2 N=47 Study in Advanced Solid Tumors
Solid Tumor
Primary: Total Cisplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) — 324; 338 micrograms*hour/milliliters…
Phase 2 N=215 Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
Schizophrenia
Primary: Change From Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS 1-22 Composite Score) at Week 12 — -13.50; -10.91; -11.21 Score on a Scale — p=0.267